Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Authors: Christopher Sorli, Shin‐ichi Harashima, George Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas K. Hansen, Stephen C. Bain - The Lancet 2017 cited by 707